| Tramiprosate in mild-to-moderate Alzheimer’s disease–a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study) PS Aisen, S Gauthier, SH Ferris, D Saumier, D Haine, D Garceau, ... Archives of Medical Science 7 (1), 102-111, 2011 | 329 | 2011 |
| Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease S Salloway, S Chalkias, F Barkhof, P Burkett, J Barakos, D Purcell, J Suhy, ... JAMA neurology 79 (1), 13-21, 2022 | 326 | 2022 |
| Standardization of analysis sets for reporting results from ADNI MRI data BT Wyman, DJ Harvey, K Crawford, MA Bernstein, O Carmichael, PE Cole, ... Alzheimer's & Dementia 9 (3), 332-337, 2013 | 259 | 2013 |
| Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer’s disease CR Jack Jr, F Barkhof, MA Bernstein, M Cantillon, PE Cole, C DeCarli, ... Alzheimer's & Dementia 7 (4), 474-485. e4, 2011 | 251 | 2011 |
| Effect of tramiprosate in patients with mild-to-moderate Alzheimer’s disease: exploratory analyses of the MRI sub-group of the Alphase study S Gauthier, PS Aisen, SH Ferris, D Saumier, A Duong, D Haine, ... JNHA-The Journal of Nutrition, Health and Aging 13, 550-557, 2009 | 162 | 2009 |
| 1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS J Suhy, WD Rooney, DE Goodkin, AA Capizzano, BJ Soher, AA Maudsley, ... Multiple Sclerosis Journal 6 (3), 148-155, 2000 | 140 | 2000 |
| The influence of biological and technical factors on quantitative analysis of amyloid PET: points to consider and recommendations for controlling variability in longitudinal data ME Schmidt, P Chiao, G Klein, D Matthews, L Thurfjell, PE Cole, ... Alzheimer's & Dementia 11 (9), 1050-1068, 2015 | 121 | 2015 |
| Early detection and longitudinal changes in amyotrophic lateral sclerosis by 1H MRSI J Suhy, RG Miller, R Rule, N Schuff, J Licht, V Dronsky, D Gelinas, ... Neurology 58 (5), 773-779, 2002 | 117 | 2002 |
| Amyloid PET screening for enrichment of early-stage Alzheimer disease clinical trials: experience in a phase 1b clinical trial J Sevigny, J Suhy, P Chiao, T Chen, G Klein, D Purcell, J Oh, A Verma, ... Alzheimer Disease & Associated Disorders 30 (1), 1-7, 2016 | 114 | 2016 |
| Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer’s disease study cohorts from phase 3 trials of semagacestat and solanezumab C Carlson, W Estergard, J Oh, J Suhy, CR Jack Jr, E Siemers, J Barakos Alzheimer's & Dementia 7 (4), 396-401, 2011 | 86 | 2011 |
| Reduced NAA in motor and non‐motor brain regions in amyotrophic lateral sclerosis: a cross‐sectional and longitudinal study RR Rule, J Suhy, N Schuff, DF Gelinas, RG Miller, MW Weiner Amyotrophic lateral sclerosis and other motor neuron disorders 5 (3), 141-149, 2004 | 86 | 2004 |
| Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's … DLG Hill, AJ Schwarz, M Isaac, L Pani, S Vamvakas, R Hemmings, ... Alzheimer's & Dementia 10 (4), 421-429. e3, 2014 | 83 | 2014 |
| Neuroradiological findings in vascular dementia A Guermazi, Y Miaux, A Rovira-Cañellas, J Suhy, J Pauls, R Lopez, ... Neuroradiology 49, 1-22, 2007 | 81 | 2007 |
| 1H MRSI predicts surgical outcome in MRI-negative temporal lobe epilepsy J Suhy, KD Laxer, AA Capizzano, P Vermathen, GB Matson, NM Barbaro, ... Neurology 58 (5), 821-823, 2002 | 68 | 2002 |
| Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with anti-amyloid beta therapy J Barakos, D Purcell, J Suhy, S Chalkias, P Burkett, CM Grassi, ... The Journal of Prevention of Alzheimer's Disease 9 (2), 211-220, 2022 | 57 | 2022 |
| Amyloid‐related imaging abnormalities from trials of solanezumab for Alzheimer's disease C Carlson, E Siemers, A Hake, M Case, R Hayduk, J Suhy, J Oh, ... Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 2 (1), 75-85, 2016 | 49 | 2016 |
| An enzyme-generated fragment of tau measured in serum shows an inverse correlation to cognitive function K Henriksen, Y Wang, MG Sørensen, N Barascuk, J Suhy, JT Pedersen, ... PLoS One 8 (5), e64990, 2013 | 49 | 2013 |
| Alzheimer’s disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology B Vellas, H Hampel, ME Rougé-Bugat, M Grundman, S Andrieu, ... The journal of nutrition, health & aging 16, 339-345, 2012 | 46 | 2012 |
| Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease AJ Schwarz, KL Sundell, A Charil, MG Case, RK Jaeger, D Scott, ... Alzheimer's & Dementia: Translational Research & Clinical Interventions 5 …, 2019 | 41 | 2019 |
| Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer’s disease MW Weiner, C Sadowsky, J Saxton, RK Hofbauer, SM Graham, SY Yu, ... Alzheimer's & Dementia 7 (4), 425-435, 2011 | 40 | 2011 |
